Target Group Remains Pre-Revenue, Relies on Capital Injections

TL;DR

**CBDY is a pre-revenue gamble; avoid unless you're betting on a future miracle.**

AI Summary

Target Group Inc. (CBDY) filed its 10-Q for the period ending June 30, 2025, revealing a continued focus on its medicinal chemicals and botanical products segment. The company reported no revenue for the six months ended June 30, 2025, consistent with the prior year, indicating it remains in a developmental or pre-revenue stage. Net income figures were not explicitly detailed as positive, with the company's retained earnings showing a deficit, suggesting ongoing operational losses. Key business changes include the continued accumulation of additional paid-in capital, which stood at a significant amount as of June 30, 2025, indicating capital injections. Risks primarily revolve around the lack of revenue generation and reliance on external financing, as evidenced by the capital structure. The strategic outlook appears to involve continued investment in operations, potentially through advisory and consultancy services, as noted for the six months ended June 30, 2025, to advance its business model in the medicinal chemicals and botanical products sector.

Why It Matters

For investors, Target Group's continued lack of revenue and reliance on additional paid-in capital signals a high-risk, speculative investment, as the company is still in a developmental phase without clear market traction. Employees face uncertainty given the pre-revenue status, with job security potentially tied to ongoing capital raises. Customers are not directly impacted yet, as the company's products are not generating sales. In the broader market, CBDY's situation highlights the challenges faced by small-cap companies in the competitive medicinal chemicals and botanical products sector, where significant capital is needed before commercialization.

Risk Assessment

Risk Level: high — The risk level is high because Target Group Inc. reported no revenue for the six months ended June 30, 2025, and has a history of name changes (Chess Supersite Corp, River Run Acquisition Corp), indicating potential instability or pivots. The company's reliance on additional paid-in capital to sustain operations without generating sales presents a significant going concern risk.

Analyst Insight

Investors should exercise extreme caution and consider avoiding CBDY shares until the company demonstrates a clear path to revenue generation and profitability. This information suggests a speculative investment, suitable only for those with a high-risk tolerance and a long-term horizon, willing to bet on future product development and market entry.

Financial Highlights

revenue

$0

revenue Growth

0.00%

Revenue Breakdown

Key Numbers

• $0 — Revenue (for the six months ended June 30, 2025, indicating pre-revenue status)
• 2025-06-30 — Period End Date (the reporting period for this 10-Q filing)
• 0001586554 — Central Index Key (CIK) (unique identifier for Target Group Inc. with the SEC)
• 10-Q — Form Type (quarterly report filed by Target Group Inc.)

Key Players & Entities

• Target Group Inc. (company) — filer of the 10-Q
• CBDY (company) — ticker symbol for Target Group Inc.
• 03 Life Sciences (company) — organization name associated with the filer
• Visava Inc. (company) — entity mentioned in relation to measurement inputs
• Chess Supersite Corp (company) — former name of Target Group Inc.
• River Run Acquisition Corp (company) — former name of Target Group Inc.
• SEC (regulator) — recipient of the 10-Q filing
• FASB (regulator) — standard-setting body for accounting principles

FAQ

Risk Factors

• Lack of Revenue Generation [high — financial]: The company reported $0 revenue for the six months ended June 30, 2025, consistent with the prior year. This indicates a continued pre-revenue status, posing a significant risk to the company's ability to achieve profitability and sustain operations.
• Reliance on External Financing [high — financial]: The company's capital structure shows significant accumulation of additional paid-in capital, indicating a heavy reliance on capital injections from investors to fund operations. This dependence exposes the company to risks associated with market conditions and investor sentiment.
• Ongoing Operational Losses [high — operational]: The company's retained earnings show a deficit, suggesting persistent operational losses. Without revenue generation, the company will continue to incur losses, increasing the need for further financing.
• Developmental Stage Business Model [medium — operational]: The company is focused on advancing its business model in the medicinal chemicals and botanical products sector, which appears to be in a developmental stage. This implies a long path to commercialization and potential for unforeseen challenges.

Industry Context

Target Group Inc. operates within the medicinal chemicals and botanical products sector, which is characterized by significant research and development investment and stringent regulatory oversight. The industry is driven by innovation in drug discovery and the increasing demand for natural and plant-based therapeutics. Companies in this space often face long development cycles and high failure rates.

Regulatory Implications

As a company in the medicinal chemicals and botanical products sector, Target Group Inc. is subject to regulations from bodies like the FDA. Compliance with Good Manufacturing Practices (GMP) and other health and safety standards is critical. Any delays or failures in regulatory approval processes can significantly impact the company's ability to bring products to market.

What Investors Should Do

1. Monitor future revenue generation closely.
2. Assess the sustainability of capital injections.
3. Evaluate the progress in the medicinal chemicals and botanical products segment.

Key Dates

• 2025-06-30: 10-Q Filing Period End — Marks the end of the reporting period for the quarterly financial statements.
• 2025-08-12: 10-Q Filing Date — The date the company officially submitted its quarterly report to the SEC.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a continuing disclosure by public companies. (This document provides the latest financial and business update for Target Group Inc.)

Additional Paid-In Capital

The amount of money a company receives from selling stock above its par value. (A significant increase here indicates substantial capital injections, highlighting the company's reliance on external funding.)

Retained Earnings

The cumulative amount of net income that a company has retained over time, rather than distributing as dividends. (A deficit in retained earnings signifies that the company has accumulated losses, indicating it is not yet profitable.)

Medicinal chemicals and botanical products

An industry segment focused on the development and production of chemicals derived from medicinal plants or used in pharmaceutical applications. (This is the primary business segment Target Group Inc. is focusing on.)

Year-Over-Year Comparison

The 10-Q for the period ending June 30, 2025, shows no change in revenue, remaining at $0, consistent with the prior year's reporting period. This indicates a persistent pre-revenue status for Target Group Inc. Specific details on net income, operating margins, and cash positions were not readily available for direct comparison, but the continued deficit in retained earnings suggests ongoing operational losses. The accumulation of additional paid-in capital also points to continued reliance on external financing, a trend likely consistent with the previous reporting period.

Key Financial Figures

• $0.0001 — g) of the Act: Common Stock, Par Value $0.0001 Indicate by check mark whether the re
• $4,627,695 — tly completed second fiscal quarter was $4,627,695 as of June 30, 2024. State the number

Filing Documents

• tmb-20250630x10q.htm (10-Q) — 1771KB
• tmb-20250630xex10d37.htm (EX-10.37) — 60KB
• tmb-20250630xex31d1.htm (EX-31.1) — 11KB
• tmb-20250630xex31d2.htm (EX-31.2) — 11KB
• tmb-20250630xex32d1.htm (EX-32.1) — 5KB
• 0001410578-25-001696.txt ( ) — 7755KB
• tmb-20250630.xsd (EX-101.SCH) — 65KB
• tmb-20250630_cal.xml (EX-101.CAL) — 53KB
• tmb-20250630_def.xml (EX-101.DEF) — 210KB
• tmb-20250630_lab.xml (EX-101.LAB) — 435KB
• tmb-20250630_pre.xml (EX-101.PRE) — 373KB
• tmb-20250630x10q_htm.xml (XML) — 1241KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION Item 1. Condensed Consolidated Interim Financial Statements (Unaudited) 3 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 4 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 12 Item 4.

Controls and Procedures

Controls and Procedures 12

– OTHER INFORMATION

PART II – OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 13 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 13 Item 3. Defaults Upon Senior Securities 13 Item 4. Mine Safety Disclosures 13 Item 5. Other Information 13 Item 6. Exhibits 14 2 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS

ITEM 1. UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS. TARGET GROUP INC. UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS INDEX Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 F-1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2025 and 2024 (Unaudited) F-2 Condensed Consolidated Statements of Stockholders' Deficit for the three and six months ended June 30, 2025 and 2024 (Unaudited) F-3 Condensed Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024 (Unaudited) F-7 Notes to Condensed Consolidated Interim Financial Statements (Unaudited) F-8 - F-25 3 Table of Contents TARGET GROUP INC. CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 $ $ (unaudited) ASSETS Current assets Cash 837,497 1,869,767 Restricted cash 8,430 7,992 Accounts receivable, net of allowance Note 3 311,894 77,092 Inventory Note 4 976,513 882,279 Prepaid asset 41,415 39,268 Convertible note receivable Note 5 73,300 139,000 Interest receivable Note 5 21,846 29,334 Sales tax recoverable, net of allowance Note 6 35,663 53,674 Other receivable Note 10 3,665 3,475 Total current assets 2,310,223 3,101,881 Long term assets Fixed assets Note 7 3,982,555 4,185,559 Goodwill Note 9 261,228 247,685 Operating lease right-of-use assets Note 11 36,709 38,408 Total long term assets 4,280,492 4,471,652 Total assets 6,590,715 7,573,533 LIABILITIES AND STOCKHOLDERS' DEFICIENCY Current liabilities Bank overdraft 506 506 Accounts payable and accrued liabilities 2,092,023 3,092,563 Payable to related parties, net Note 10 7,704,517 9,854,719 Operating lease liability - Current portion Note 11 161,520 140,202 Convertible promissory notes, net Note 12 480 480 Derivat

View Full Filing

View this 10-Q filing on SEC EDGAR